Source: Visionstate.
  • Visionstate (VIS) has announced a private placement for gross proceeds of up to $500,000
  • The company will issue up to 12,500,000 common shares priced at $0.04 per share
  • Visionstate invests in the research and development of promising new technology in the realm of the Internet of Things
  • Visionstate Corp. (VIS) is unchanged on the day, trading at C$0.03 per share at 2:45 pm ET

Visionstate (VIS) has announced a private placement for gross proceeds of up to $500,000.

The company will issue up to 12,500,000 common shares priced at $0.04 per share.

Each share purchased under the offering will include one warrant that will entitle the holder to acquire an additional common share at $0.05 for up to 24 months.

The net proceeds will be used for marketing and sales initiatives, funding research and development, operating capital and investigating a US quotation on the OTCQB.

Visionstate invests in the research and development of promising new technology in the realm of the Internet of Things, big data and analytics, and sustainability.

The footprint of its WANDA™ smart device now extends to hospitals, airports, shopping centers, and other public facilities across North America.

Visionstate Corp. (VIS) is unchanged on the day, trading at C$0.03 per share at 2:45 pm ET.

More From The Market Online

Westinghouse Electric files for US IPO

Westinghouse Electric Company, jointly owned by Cameco and Brookfield Renewable Partners, confidentially filed for a US IPO.

The 5-Minute Investor Podcast, Ep. 72: The next AI gold rush is copper

Check out ep. 72 of The 5-Minute Investor Podcast, with analysis on copper stocks Freeport-McMoRan and Capstone Copper.

Buzz on the Bullboards: Contracts, cashflows, and delistings

Uncertainty around Iran has weighed on sentiment, reminding investors that even strong stories can be overshadowed by geopolitical risk.

EU authorizes new COVID vaccine from Pfizer and BioNTech

The EU grants marketing authorization to Pfizer and BioNTech's COVID-19 vaccine targeting the new XFG variant.